Ceapro Inc. Demonstrates First Water Soluble Solid Nanodispersion Formulation of CoQ10 Utilizing its PGX Enabling Technology

Announces positive results from the first phase of a project to develop a functional energy drink at the 16th European Meeting on Supercritical Fluid Technologies held in Lisbon, Portugal
EDMONTON, ALBERTA--(May 4, 2017) - Ceapro Inc.(TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of the first development phase of a project entitled, "Beta glucan with coenzyme Q10 ("CoQ10"): A novel ingredient for functional beverages." This project included two studies, which were conducted at the University of Alberta by Dr. Feral Temelli's team along with Ceapro researchers.
Read more: Ceapro Inc ( CZO )

Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases

BOSTON, MA--(May 03, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)
Pieris to receive $57.5 million USD in upfront and near-term milestone payments
Pieris has the potential to receive development-dependent milestones and eventual commercial payments for all products not exceeding $2.1 billion as well as tiered royalties
For programs co-developed by Pieris, the Company will be entitled to receive increased royalties or a gross margin share on worldwide sales, dependent on the level of investment to which Pieris commits
Read more: Pieris Pharmaceuticals Inc ( PIRS )

Microbix Consults with FDA Regarding Plans for Kinlytic(R) Urokinase

Project Activity Now Expected to Accelerate
TORONTO, ONTARIO--(May 1, 2017) - Microbix Biosystems Inc. (TSX:MBX) ("Microbix" or the "Company") a developer and marketer of biological products and technologies, announces that it has consulted with the U.S. Food and Drug Administration (the "FDA") regarding the Company's plans to return its thrombolytic biologic drug, Kinlytic® Urokinase ("Kinlytic"), to the U.S. market.
Microbix believes the results of its consultation will accelerate its work to obtain financing, complete its re-launch program and then submit an application to FDA for re-approval in the U.S. market. The Company has already received expressions of interest to license or acquire Kinlytic and to provide full funding for its re-launch program. Following its consultation with FDA, the Company now intends to accelerate its work to conclude such an agreement. Microbix has also established that Kinlytic may be produced via contract manufacturing, a factor that should shorten the timeline of its return to market. The Company plans to retain a significant interest in the economics of Kinlytic following an agreement to enable its re-launch program.
Read more: Microbix Biosystems ( MBX )

Ampio Initiates Pivotal Trial of Ampion ™

ENGLEWOOD, Colo., May 1, 2017 -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces initiation of a single injection study to meet the "unmet medical need" of treating the severe pain and loss of function associated with Kellgren-Lawrence (KL) grade 4 osteoarthritis of the knee (OAK) with a primary endpoint that follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clincal Trials (OMERACT) OMERACT-OARSI responder rate.
Dr. David Bar-Or, Ampio's Chief Science Officer, clarified, "In compliance with FDA guidance, this trial will be smaller than our prior trials with 171 patients, randomization of 6 to 1 (Ampion™/Saline) on patients with severe OAK, defined radiologically as KL 4 patients. 
Read more: Ampio Pharmaceuticals ( AMPE )

Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML

Interim Efficacy and Safety Data from Ongoing Phase 2 Study in Follicular Lymphoma and DLBCL Selected for Plenary Presentation at the International Conference on Malignant Lymphoma
Management to Host Conference Call on June 14 at 10:30 a.m. ET
CAMBRIDGE, Mass., April 25, 2017 - Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to tazemetostat, the Company’s first-in-class EZH2 inhibitor, for the treatment of patients with relapsed or refractory follicular lymphoma, either wild type EZH2 or with EZH2 activating mutations. Fast Track designation is intended to provide expedited processes for the development and FDA review of drugs that may reduce development time and costs associated with bringing a drug to market.
Read more: Epizyme Inc ( EPZM )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker